1-4 of 4
Esther C. W. Breij
Close
Sort by
Journal Articles

Hexabody-CD38, a Novel CD38 Antibody with a Hexamerization Enhancing Mutation, Demonstrates Enhanced Complement-Dependent Cytotoxicity and Shows Potent Anti-Tumor Activity in Preclinical Models of Hematological Malignancies

Bart ECG De Goeij, PhD, Maarten L Janmaat, PhD, Grietje Andringa, Laurens Kil, Berris Van Kessel, Kristine A. Frerichs, MD, Andreas Lingnau, Andreas Freidig, Tuna Mutis, MD PhD, A. Kate Sasser, Esther C. W. Breij, Niels W. C. J. Van De Donk, MD PhD, Tahamtan Ahmadi, David Satijn
Journal: Blood
Blood (2019) 134 (Supplement_1): 3106.
https://doi.org/10.1182/blood-2019-125788
Published: 2019
Journal Articles

Duohexabody-CD37, a Novel Bispecific Antibody with a Hexamerization-Enhancing Mutation Targeting CD37, Demonstrates Superior Complement-Dependent Cytotoxicity in Preclinical B-Cell Malignancy Models

Simone C. Oostindie, MSc, Hilma J. Van Der Horst, MSc, Marije B. Overdijk, PhD, Kristin Strumane, PhD, Sandra Verploegen, PhD, Margaret A. Lindorfer, PhD, Erica M. Cook, B.A., Martine E.D. Chamuleau, MD, Tuna Mutis, PhD, Janine Schuurman, PhD, A. Kate Sasser, PhD, Ronald P. Taylor, PhD, Paul W. H. I. Parren, PhD, Frank J. Beurskens, PhD, Esther C. W. Breij, PhD
Journal: Blood
Blood (2018) 132 (Supplement 1): 4170.
https://doi.org/10.1182/blood-2018-99-114723
Published: 2018
Journal Articles

Targeting CD37 in B-Cell Malignancies Using the Novel Therapeutic Duohexabody-CD37 Results in Efficient Killing of Tumor B-Cells Ex Vivo Via Complement-Dependent Cytotoxicity, Even in Relapsed and/or Refractory Patient Samples

Hilma J. Van Der Horst, MSc, Simone C. Oostindie, MSc, Saskia AGM Cillessen, MSc, Anne T Gelderloos, MSc, Marije B Overdijk, Martine E.D. Chamuleau, MD, Esther C. W. Breij, PhD, Tuna Mutis, PhD
Journal: Blood
Blood (2018) 132 (Supplement 1): 4179.
https://doi.org/10.1182/blood-2018-99-115886
Published: 2018
Journal Articles

Duobody-CD3xCD20 Shows Unique and Potent Preclinical Anti-Tumor Activity in Vitro and In Vivo , and Is Being Evaluated Clinically in Patients with B-Cell Malignancies

Ida H. Hiemstra, PhD, Patrick J. Engelberts, BS, Bart de Jong, BS, Danita H Schuurhuis, PhD, Theodora W. Salcedo, PhD DABT, Sandra Verploegen, PhD, Marten van der Zee, PhD, Arnout F. Gerritsen, PhD, Nedjad Losic, PhD, Sjeng Horbach, PhD, Roberto Oliveri, MD PhD, Jeroen J. Lammerts van Bueren, PhD, Pernille Autzen Usher, PhD, Janine Schuurman, PhD, Paul W. H. I. Parren, PhD, Esther C. W. Breij, PhD
Journal: Blood
Blood (2018) 132 (Supplement 1): 1664.
https://doi.org/10.1182/blood-2018-99-115957
Published: 2018